IP Library Granted Patent US 8,975,386
Granted Patent B2
US 8,975,386 · App. 13/636,510 · Granted Mar 10, 2015

Crystalline forms of a macrolide, and uses therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,386
App. No.
13/636,510
Granted
Mar 10, 2015
Kind
B2
Abstract

New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.

Claims (21)

1. A process for the preparation of Form I of CEM-101, the process comprising the step of adding a solution of CEM-101 in a water miscible, polar organic solvent to water at a temperature below 50° C.

2. The process of claim 1 wherein the Form I of CEM-101 is substantially free of other physical forms.

3. The process of claim 1 further comprising one or more of the following steps:

heating the solution of CEM-101;

filtering the solution of CEM-101;

reducing the volume of the solution of CEM-101 by evaporation; and

stirring the water during addition of the solution of CEM-101.

4. The process of claim 1 wherein the solvent is acetone, methanol or ethanol, or a combination thereof.

5. The process of claim 1 wherein the solvent is acetone.

6. The process of claim 1 wherein the solution is added to water at a temperature of about 10° C. to about 30° C.

7. A process for the preparation of Form II of CEM-101, the process comprising the step of adding water to a solution of CEM-101 in a water miscible, polar organic solvent.

8. The process of claim 7 wherein the Form II of CEM-101 is substantially free of other physical forms.

9. The process of claim 7 further comprising one or more of the following steps:

filtering the solution of CEM-101;

reducing the volume of the solution of CEM-101 by evaporation; and

stirring the solution of CEM-101 during addition of the water.

10. The process of claim 7 wherein the solvent is acetone, acetonitrile, 1,4-dioxane, methanol or ethanol, or a combination thereof.

11. The process of claim 7 wherein the solution of CEM-101 is above ambient temperature.

12. A process of purifying CEM-101 comprising converting one or more forms or mixtures of forms of the CEM-101 into Form I or Form II substantially free of other physical forms.

13. The process of claim 12 further comprising the step of adding a solution of the CEM-101 in a water miscible, polar organic solvent to water at a temperature below 50° C.

14. The process of claim 12 further comprising the step of adding water to a solution of the CEM-101 in a water miscible, polar organic solvent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →